FDA Approves Brytly as First Nonprescription Apraclonidine Eye Drop

The U.S. FDA has approved Brytly (apraclonidine ophthalmic solution, 0.125%) as a new nonprescription eye drop. It is intended for adults and children aged 12 and older to relieve eye redness from minor irritations, marking the first over-the-counter product containing apraclonidine. This approval provides consumers with a new accessible option for eye care.